• 1
    Parsons ME. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Eur J Gastroenterol Hepatol 1996; 8(Suppl. 1): 1520.
  • 2
    Huber R, Hartmann M, Bliesath H, Lühmann R, Steinijans VW, Zech K. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996; 34(5): 18594.
  • 3
    Steinijans VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther 1996; 34(Suppl. 1): 3150.
  • 4
    Bochenek W, Miska D, Beg M. Efficacy of pantoprazole in reflux erosive esophagitis (EE) is dose related. Digestion 1998; 59(Suppl. 3): 601601.
  • 5
    Reill L, Erhardt F, Fischer R, Huber R, Londong W. Dose-response of pantoprazole 20, 40 and 80 mg on 24–hour intragastric pH and serum gastrin in man. Gut 1993; 34(Suppl. 4): F251F251.
  • 6
    Katz PO, Paoletti V, Bochenek W, Steinberg M. A double-blind, randomized, crossover, dose-response study of the effects of 10, 20, or 40 mg of oral pantoprazole taken once daily on intragastric pH in healthy adults. Gastroenterology 1999; 116(4, Part 2): A208A208(Abstract).
  • 7
    Savary M & Miller G. The esophagus. In: Savary M, Miller G, eds. Handbook and Atlas of Endoscopy. Soluthurn, Switzerland: Verlag Gassmann AG, 1978: 119–205.
  • 8
    Savarino V, Mela GS, Zentilin P, et al. Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy. Dig Dis Sci 1994; 39(1): 1618.
  • 9
    Lind T, Havelund T, Carlsson R, et al. Heartburn in patients without oesophagitis. Scand J Gastroenterol 1997; 32: 9749.
  • 10
    Lauritsen K. Management of endoscopy-negative reflux disease: progress with short-term treatment. Aliment Pharmacol Ther 1997; 11(Suppl. 1): 8792.
  • 11
    Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 96573.
  • 12
    Bate CM, Booth SN, Crowe JP, Hepworth-Jones B, Taylor MD, Richardson PDI. Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? Aliment Pharmacol Ther 1993; 7: 5017.
  • 13
    SAS Institute Inc. SAS/STAT® Useŕs Guide, Version 6, 4th edn., Vol. 1. Cary, NC: SAS Institute Inc., 1990.
  • 14
    Van Zyl JH, De Grundling HK, Van Rensburg CJ, et al. Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomised, double-blind, parallel, and multicenter study. Eur J Gastroenterol Hepatol 2000; 12: 197202.
  • 15
    Carlsson R, Dent J, Watts R, et al. and the International GORD Study Group. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 11924.
  • 16
    Dettmer A, Vogt R, Sielaff F, Lühmann R, Schneider A, Fischer R. Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis. Aliment Pharmacol Ther 1998; 9: 86572.
  • 17
    Moola SAH, Van Rensburg CJ, Kassianides C, et al. Efficacy of pantoprazole 20 mg vs. placebo once daily in the treatment of patients with symptomatic reflux disease and endoscopically normal esophagus. Gastroenterology 1999; 116(4, Part 2): A180A180(Abstract).
  • 18
    Ramirez-Barba EJ, Di Silvio M, Dibildox M, et al. and the Mexican Pantoprazole Study Group in GERD. Superiority of 20 mg pantoprazole (Panto) vs. 150 mg × 2 ranitidine (Rani) in healing and symptom relief of patients with mild reflux oesophagitis. Gastroenterology 1998; 114(4, Part 2): A264A264(Abstract).
  • 19
    Holtmann G, Cain CR, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 116.
  • 20
    Labenz J & Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, or protective factor? Gut 1997; 41: 27780.